Skip to main content
. 2015 May 14;48(1):71–79. doi: 10.4143/crt.2015.018

Fig. 2.

Fig. 2.

Survival according to genotype in early esophageal cancer. In early esophageal cancer, FGFR4 Gly388 allele patients showed a better trend of progression-free survival (A) (p=0.079) and significantly better overall survival (C) (p=0.042) than FGFR4 Arg388 carriers in lymph node (LN)-positive patients. However, there was no difference in LN-negative patients according to genotypes (B, D).